Mass Spectrometric-Based Proteomics for Biomarker Discovery in Osteosarcoma: Current Status and Future Direction

Due to a lack of novel therapies and biomarkers, the clinical outcomes of osteosarcoma patients have not significantly improved for decades. The advancement of mass spectrometry (MS), peptide quantification, and downstream pathway analysis enables the investigation of protein profiles across a wide...

Descripción completa

Detalles Bibliográficos
Autores principales: Sirikaew, Nutnicha, Pruksakorn, Dumnoensun, Chaiyawat, Parunya, Chutipongtanate, Somchai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456544/
https://www.ncbi.nlm.nih.gov/pubmed/36077137
http://dx.doi.org/10.3390/ijms23179741

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9456544/
https://www.ncbi.nlm.nih.gov/pubmed/36077137
http://dx.doi.org/10.3390/ijms23179741

Ejemplares similares